

Exploring the phytochemical profile of *Cytinus hypocistis* (L.) L. as a source of health-promoting biomolecules behind its *in vitro* bioactive and enzyme inhibitory properties

Ana Rita SILVA^{a,b}, José PINELA^a, Maria Inês DIAS^a, Ricardo C. CALHELHA^a,
Maria José ALVES^a, Andrei MOCAN^c, Pablo A. GARCÍA^b, Lillian BARROS^{a,*},
Isabel C.F.R. FERREIRA^{a,*}

^a*Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal*

^b*Departamento de Ciencias Farmacéuticas. Facultad de Farmacia, CIETUS-IBSAL, Universidad de Salamanca, 37007 Salamanca, España.*

^c*Department of Pharmaceutical Botany, “Iuliu Hațieganu” University of Medicine and Pharmacy, 23 Gheorghe Marinescu Street, 400337 Cluj-Napoca, Romania.*

*Corresponding authors: Tel.+351 273 303219; fax +351 273 325405. E-mail address: iferreira@ipb.pt (I.C.F.R. Ferreira); Tel.+351 273 303285; fax +351 273 325405. E-mail address: lillian@ipb.pt (L. Barros)

Abstract

Cytinus hypocistis whole plant and its three different parts (petals, stalks, and nectar) were chemically characterised and their biological properties evaluated. A total of 17 phenolic compounds were identified, being galloyl-bis-HHDP-glucose the most abundant. All the tested extracts showed high antioxidant capacity, with the petals exhibiting the most promising results both in the OxHLIA ($IC_{50} = 0.279$ ng/mL) and TBARS ($IC_{50} = 0.342$ ng/mL) assays. For the antidiabetic and anti-tyrosinase enzyme inhibitory assays, the stalk extract presented the lowest IC_{50} values, 0.039 mg/mL and 0.09 mg/mL, respectively. Regarding antibacterial activity, all tested extracts displayed broad-spectrum microbial inhibition against both Gram-positive and Gram-negative bacteria. Similarly, all extracts displayed effective anti-proliferation activity against four tested tumour cell lines (NCI-H460, HeLa, HepG2, and MCF-7), with no toxicity observed for a non-tumour cell line. Considering the anti-inflammatory activity, the petals showed the highest NO inhibition ($IC_{50} = 127$ μ g/mL). These results point *C. hypocistis* as a promising source of health-promoting biomolecules.

Keywords: *Cytinus hypocistis* (L.) L.; phytochemical profile; tannins; bioactive properties; cellular/enzymatic assays.

1 **1. Introduction**

2 Medicinal plants have been used as medicine by humans for thousands of years in the
3 form of crude drugs such as teas, tinctures, poultices, and later through more sophisticated
4 techniques as compound isolation (Balunas and Kinghorn, 2005). After a period of
5 indifference, in which synthetic compounds were preferred, there is an increasing interest
6 in studying the active principles behind plants therapeutic properties (Graça et al., 2016).
7 The pharmaceutical industry faces unprecedented challenges, with fewer compounds
8 being found, tested, and released to the public mainly due to the several drawbacks of the
9 process to approve new drugs, humans have once again turned to Nature to mitigate the
10 relative void of combinatorial chemistry to find new compounds (Phillipson, 2007).
11 Polyphenols are the largest and the most widespread group of secondary metabolites in
12 plants. With a great variety of structures, ranging from simple compounds with few
13 aromatic rings to highly polymeric substances, such as flavonoids, stilbenes, lignans, and
14 phenolic acids. These compounds are commonly found in both edible and inedible plants,
15 and have been reported to have multiple biological effects (Okuda and Ito, 2011).
16 Tannins, being one of the most structurally diverse polyphenols, have been reported to
17 play a crucial role in plant defence against pathogens, herbivores and climatic changes.
18 Structurally, tannins can be subdivided into two major groups: condensed tannins (or
19 proanthocyanidins), which are of flavonoid origin, and hydrolysable tannins, which are
20 defined as esters of gallic acid with a polyol moiety, mainly β -D-glucose (Petersen et al.,
21 2010). The last group can be further subdivided into gallotannins and ellagitannins, and
22 their basic building block is β -glucogallin (1-*O*-galloyl- β -D glucopyranose) (Petersen et
23 al., 2010). Typical complex gallotannins are the addition of gallic acid moieties and the
24 formation of depsidic *meta*-bonds between suitably positioned galloyl residues in the
25 molecule. Ellagitannins, however, are derived from pentagalloylglucose through an

26 oxidative linkage of the galloyl moieties, leading to the formation of 3,4,5,3',4',5'-
27 hexahydroxydiphenoyl (HHDP) moieties; they are named after their characteristic
28 hydrolysis product, ellagic acid, the dilactone of HHDP. Whereas gallotannins seem to
29 be mainly restricted to woody dicotyledonous plants, ellagitannins are more widely
30 spread in the plant kingdom (Petersen et al., 2010).

31 *Cytinus hypocistis* (L.) L. (*Cytinaceae* family) is an endophytic parasitic plant on various
32 members of the *Cistaceae* family occurring in the Mediterranean region. Apart from used
33 as famine food, it was also applied in a wide variety of traditional healthcare practices,
34 including dysentery, tumour of the throat, and eye inflammation treatment (Zucca et al.,
35 2015). Although its biological properties were potentially attributed to its hydrolysable
36 tannin content, to the authors' best knowledge, its chemical composition is largely
37 unknown, and active biomolecules are not yet identified (Magiatis et al., 2001; Zucca et
38 al., 2015). Therefore, the present work aims at chemically characterise *C. hypocistis* and
39 evaluate its antioxidant, antibacterial, anti-tyrosinase, antidiabetic, anti-inflammatory and
40 anti-proliferative properties.

41

42 **2. Materials and methods**

43 2.1. Standards and reagents

44 α -Glucosidase from *Saccharomyces cerevisiae*, trichloroacetic acid, mushroom
45 tyrosinase, sulforhodamine B, ellipticine, dexamethasone, trypan blue,
46 lipopolysaccharide (LPS), Tris(hydroxymethyl)aminomethane, thiobarbituric acid
47 (TBA), 2,2'-azobis(2-amidinopropane)dihydrochloride (AAPH), 3,4-dihydroxy-L-
48 phenylalanine (L-DOPA), and Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
49 carboxylic acid) were acquired from Sigma Chemical Co. (Saint Louis, MO, USA). *p*-
50 Iodonitrotetrazolium chloride (INT) was acquired from PanReac AppliChem (Barcelona,

51 Spain), and Tryptic Soy Broth (TSB) and Mueller-Hinton (MHB) from Biolab®
52 (Hungary). Dulbecco's Modified Eagle's and RPMI-1640 mediums, fetal bovine serum
53 (FBS), Hank's balanced salt solution (HBSS), L-glutamine, nonessential amino acid
54 solution (2 mM), penicillin/streptomycin solutions, trypsin, and EDTA were acquired
55 from Hyclone (Logan, USA). Acetonitrile 99.9%, of High Performance Liquid
56 Chromatography (HPLC) grade, and dimethyl sulfoxide (DMSO) were acquired from
57 Fisher Scientific (Lisbon, Portugal) and formic acid from PanReac (Barcelona, Spain).
58 Phenolic compound standards (catechin, gallic acid, and ellagic acid) were purchased
59 from Extrasynthese (Genay, France). All other chemicals were of analytical grade and
60 purchased from common sources. Water was treated by means of a Milli-Q water
61 purification system (TGI Pure Water Systems, Greenville, SC, USA).

62

63 2.2. Sampling and extracts preparation

64 *Cytinus hypocistis* (L.) L. subsp. *macranthus* Wettst plants were collected in July 2018
65 from the host species *Halimium lasianthum* subsp. *alyssoides* (Lam.) Greuter at three
66 different locations in Castro Daire, Portugal. Plant identification, characterization, and
67 preparation were conducted as previously described by Silva et al. (2019). **Figure 1-A**
68 shows how lyophilised plants were separated into four different samples, whole plant
69 (CH), petals (PCH), stalks (SCH) and nectar (NCH). Hydroethanolic extracts were then
70 prepared as described by Bessada et al. (2016) using ethanol/water (80:20, v/v) as
71 extraction solvent.

72

73 2.3. Phenolic profile characterization

74 Phenolic compounds were determined by HPLC-DAD-ESI/MSⁿ (Dionex Ultimate 3000
75 UPLC, Thermo Scientific, San Jose, CA, USA) as previously described (Bessada et al.,

2016). Detection was carried out with a DAD using 280 nm, 330 nm, and 370 nm as the preferred wavelengths and a mass spectrometer connected to the HPLC system. Mass spectrometric detection was performed by means of a Linear Ion Trap LTQ XL (Thermo Finnigan, San Jose, CA, USA) equipped with an ESI source and spectrums were recorded in negative ion mode (m/z 100 – 1700). The phenolic compounds were characterized according to their UV spectra, fragmentation pattern, their retention times, and comparison with available standards. For quantification, calibration curves were obtained from commercial standards: gallic acid ($y = 131538x + 292163$; $R^2 = 0.9998$; LOD = 0.68 $\mu\text{g/mL}$; LOQ = 1.61 $\mu\text{g/mL}$); catechin ($y = 84950x + 23200$; $R^2 = 0.9999$; LOD = 0.17 $\mu\text{g/mL}$; LOQ = 0.68 $\mu\text{g/mL}$); ellagic acid ($y = 26719x - 317255$; $R^2 = 0.9996$; LOD = 0.10 $\mu\text{g/mL}$; LOQ = 0.48 $\mu\text{g/mL}$). The results were expressed in mg/g of extract.

87

2.4. Evaluation of bioactive properties

2.4.1. Antioxidant activity

The oxidative haemolysis (OxHLIA) and thiobarbituric acid reactive substances (TBARS) formation inhibition assays were performed following methodologies previously described by Lockowandt et al. (2019). Trolox was used as positive control.

OxHLIA assay. In a flat bottom 48-well microplate, 200 μL of erythrocytes in PBS (2.8% w/v) were mixed with 400 μL of the extract samples (0.0625-2 $\mu\text{g/mL}$ in PBS); PBS was used as control and milli-Q water for complete haemolysis. After pre-incubation at 37 °C for 10 min with shaking, AAPH (200 μL , 160 mM in PBS) was added and the optical density (690 nm) was measured every ~10 min in a microplate reader (Bio-Tek Instruments, ELX800) until complete haemolysis. The results were given as IC_{50} values, i.e., extract concentration (ng/mL) required to protect 50% of the erythrocyte population from the oxidative haemolysis for Δt of 60 min and 120 min.

101 *TBARS assay.* The brains were obtained from pig (*Sus scrofa*) of body weight ~147 Kg,
102 dissected and homogenized with a polytron in ice-cold Tris–HCl buffer (20 mM, pH 7.4)
103 to produce a 1:2 (w/v) brain tissue homogenate which was centrifuged at 3000 g for 10
104 min. The porcine brain supernatant (1:2, w/v; 0.1 mL) was incubated with the extract
105 samples (0.0625-2 µg/mL in water; 0.2 mL) plus FeSO₄ (10 µM; 0.1 mL) and ascorbic
106 acid (0.1 mM; 0.1 mL) at 37 °C for 1 h. Then, trichloroacetic (28% w/v, 0.5 mL) and
107 thiobarbituric (TBA, 2%, w/v, 0.38 mL) acids were added and the mixture was heated at
108 80 °C for 20 min. After centrifugation at 3000g for 10 min, the malondialdehyde (MDA)-
109 TBA complexes formed in the supernatant were monitored at 532 nm (Specord 200
110 spectrophotometer, Analytik Jena, Jena, Germany). The results were given as IC₅₀ values,
111 i.e., extract concentration (ng/mL) providing 50% of antioxidant activity.

112

113 2.4.2. *Antibacterial activity*

114 The extracts were tested against microbial strains isolated from different patients
115 hospitalized at the Hospital Center of Trás-os-Montes and Alto Douro (Vila Real,
116 Portugal). Five Gram-negative bacteria (*Escherichia coli*, *Proteus mirabilis*, *Klebsiella*
117 *pneumoniae*, *Pseudomonas aeruginosa* and *Morganella morganii*) and four Gram-
118 positive bacteria (*Enterococcus faecalis*, *Listeria monocytogenes*, methicillin-sensitive
119 *Staphylococcus aureus* (MSSA) and methicillin-resistant *Staphylococcus aureus*) were
120 incubated at 37 °C (24 h) in appropriate fresh medium before further analysis. Minimum
121 inhibitory concentration (MIC) was performed by the microdilution method and the rapid
122 *p*-iodonitrotetrazolium chloride (INT) colorimetric assay, following the methodology
123 previously described by Pires et al. (2018). To each well (96-well microplate) containing
124 a mixture of 190 µL of MHB/TSB and 10 µL of bacteria inoculum (standardized at
125 1.5×10⁶ CFU/mL), 200 µL of each diluted extract concentration (20 - 0.15 mg/mL in 5%

126 (v/v) DMSO/MHB) were added. The lowest extract concentration that prevented colour
127 change (yellow to pink) by inhibiting bacterial growth is described as MIC. Three
128 negative controls were prepared, one with Mueller-Hinton Broth (MHB), another with
129 the extract, and the third one with medium and antibiotic. For the Gram-negative bacteria,
130 antibiotics, such as ampicillin (20 mg/mL) and imipenem (1 mg/mL) were used as
131 positive controls, while ampicillin and vancomycin (1 mg/mL) were used for the Gram-
132 positive bacteria. The microplates were covered and incubated at 37 °C for 24 h. MIC
133 was detected adding 40 µL (0.2 mg/mL) of *p*-iodonitrotetrazolium chloride (INT) and
134 incubation the mixture at 37 °C for 30 min. For minimum bactericidal concentration
135 (MBC) determination, 50 µL of the different well mixtures (no colour change) were
136 plated on solid medium and incubated at 37 °C for 24 h. The lowest concentration
137 showing no bacteria growth was defined as MBC.

138

139 2.4.3. Antidiabetic (glucosidase inhibitory) assay

140 The α -glucosidase inhibitory assay was adapted from the methodology previously
141 described by Les et al. (2017) and Spínola and Castilho (2017). The assay was conducted
142 in a 96-well microplate with a reaction mixture containing 50 µL of extract sample diluted
143 in 50 µL of 100 mM-phosphate buffer (pH 6.8) and 50 µL yeast α -glucosidase (2 U/mL
144 in same buffer). The reaction mixture was then incubated for 10 min, followed by addition
145 of 50 µL substrate (5 mM, *p*-nitrophenyl- α -D-glucopyranoside prepared in the same
146 buffer). After 20 min of incubation, the release of *p*-nitrophenol was
147 spectrophotometrically measured at 405 nm. Individual blanks and a positive control
148 (acarbose) were prepared. The results were expressed as IC₅₀ values (mg/mL), which
149 were calculated from the inhibition percentage values achieved using the formula:
150 Inhibition (%) = $[(Abs_{control} - Abs_{sample}) / Abs_{control}] \times 100$.

151

152 *2.4.4. Tyrosinase inhibitory activity*

153 Tyrosinase inhibitory activity of the extracts was determined as previously described by
154 Chen et al. (2009), using a SPECTROstar Nano Multi-Detection Microplate Reader and
155 96-well plates (BMG Labtech, Ortenberg, Germany). Each extract sample was dissolved
156 in a mixture of water and DMSO (5%). Four wells were attributed to each sample: (A)
157 120 μL of 66 mM PBS (pH 6.8) and 40 μL of mushroom tyrosinase in PBS (46 U/mL);
158 (B) 160 μL PBS; (C) 80 μL PBS, 40 μL tyrosinase and 40 μL sample; (D) 120 μL PBS
159 and 40 μL sample extract. After incubation (10 min at room temperature), 40 μL of 2.5
160 mM L-DOPA dissolved in PBS were added to each well, and the mixtures incubated at
161 room temperature for 20 min. The absorbance of each well was measured at 475 nm, and
162 the inhibition percentage of the tyrosinase activity was calculated using the equation:
163 $\text{Inhibition (\%)} = \frac{(A-B)-(C-D)}{(A-B)} \times 100$. Kojic acid (0.10 mg/mL) was used as
164 positive control. IC_{50} values (mg/mL) were then calculated from the obtained inhibition
165 percentage values.

166

167 *2.4.5. Anti-proliferative and hepatotoxic activity*

168 Cell lines were obtained from ECACC: European Collection of Animal Cell Culture
169 (Salisbury, UK). MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung
170 carcinoma), HeLa (cervical carcinoma) and HepG2 (hepatocellular carcinoma) were the
171 tested human tumour cell lines, and the cell density determination was performed using a
172 sulforhodamine B assay previously described by Guimarães et al. (2013), where the
173 amount of pigmented cells is directly proportional to the total protein mass and, therefore,
174 to the number of bounded cells. These cell lines were treated with different concentrations
175 (0.125-0.4 mg/mL) of the extract samples dissolved in ultrapure water. For the non-

176 tumour cells, a cell culture previously prepared from a freshly harvested porcine liver
177 obtained from a local slaughter house as described (Guimarães et al., 2013), and named
178 as PLP2, was used to determine hepatotoxicity (Guimarães et al., 2013). A phase-contrast
179 microscope was used to monitor the growth of the cell cultures. The cells were sub-
180 cultured and plated in 96-well plates (density of 1.0×10^4 cells/well). Dulbecco's modified
181 eagle's medium (DMEM) was used, with 10% of fetal bovine serum (FBS), 100 U/mL of
182 penicillin, and 100 $\mu\text{g/mL}$ of streptomycin. Ellipticine was used as positive control and
183 the results were expressed as GI_{50} values (sample concentration in $\mu\text{g/mL}$ that inhibited
184 50% of the net cell growth).

185

186 *2.4.6. Anti-inflammatory activity*

187 The concentration of nitrite produced by lipopolysaccharide (LPS)-stimulation was tested
188 in a murine macrophages RAW 264.7 cell line [ECACC: European Collection of Animal
189 Cell Culture (Salisbury, UK).] Cells were treated with different concentrations (0.125-0.4
190 mg/mL) of the extract samples dissolved in ultrapure water, and the production of nitric
191 oxide (NO) was measured using the Griess Reagent System kit Promega (Madison WI,
192 USA) as formerly described by Souilem et al. (2017). Dexamethasone (50 μM) was used
193 as a positive control. The results were expressed as IC_{50} values ($\mu\text{g/mL}$), corresponding
194 to the extract concentration providing a 50% inhibition in NO production.

195

196 *2.5. Statistical analysis*

197 Three samples were analyzed and all the assays were carried out in triplicate. The results
198 were expressed as mean values \pm standard deviation (SD). Statistical analysis was
199 conducted with the aid of SPSS v. 23.0 (IBM Corp., Armonk, NY, USA). Data were
200 evaluated by a variance analysis (ANOVA) and by a Tukey's HSD test ($\alpha = 0.05$). The

201 fulfilment of the ANOVA requirements, specifically the normal distribution of residuals
202 and the homogeneity of variance, was tested by means of the Shapiro Wilk's and Levene's
203 tests, respectively. For comparison between two samples, a two-tailed paired Student's *t*-
204 test was applied to assess statistical differences ($\alpha = 0.05$).

205

206 **3. Results and discussion**

207 3.1. Composition of phenolic compounds

208 An exemplary phenolic profile of the *C. hypocistis* petals recorded at 280 nm is shown in
209 **Figure 1-B**, peak characteristics and tentative identities are presented in **Table 1** and
210 quantification is present in **Table 2**. Compounds 1-3 and 5-17 showed a UV spectra
211 coherent with hydrolysable tannins, and its galloyl and hexahydroxydiphenoyl (HHDP)
212 derivatives. According to the literature, the main characteristics in the mass spectra of
213 these compounds are the losses of a proton $[M-H]^-$, one or more ellagic acid (302 mu),
214 gallic acid (170 mu), and/or galloyl groups (152 mu) (Carocho et al., 2014). Compounds
215 number 1 and 2 were tentatively identified as galloyl-glucose and digalloyl-glucose,
216 respectively, due to the loss of a galloyl moiety characterized by a typical MS^2 fragment
217 at m/z 331. Elimination of a glucose moiety [162 mu] and subsequently formation of a
218 deprotonated gallic acid at m/z 169 were also observed. The deprotonated gallic acid
219 underwent decarboxylation with mass loss of 44 to form a trihydroxyphenol moiety at
220 m/z 125 (Tan et al., 2011). Compounds number 3 and 5 were tentatively deduced as
221 trigalloyl-glucose, with $[M-H]^-$ at m/z 635, and a typical MS^2 fragment at m/z 483,
222 indicating the loss of one galloyl group (152 mu). Product ions at m/z 465 and 313, usually
223 found on the fragmentation scheme of gallotannins, were also observed (Mena et al.,
224 2012; Tan et al., 2011). Compound number 6 ($[M-H]^-$ at m/z 937; fragment ions at m/z
225 767, 637, 467 and 301) was coherent with trigalloyl-HHDP-glucose isomers (Carocho et

226 al., 2014). Compound number 7 (tetragalloyl-glucoside; m/z 787) presented a
227 characteristic MS² fragment at m/z 635 (trigalloyl-glucose), correspondent to the loss of
228 one galloyl group (152 mu), and product ions at m/z of 617 and 465, consistent with the
229 loss of a m/z 170 gallate moiety, H₂O m/z 18 and galloyl m/z 152, respectively (Owen et
230 al., 2003). Compound number 8 presented a singly-charged pseudo-molecular ion [M-H]⁻
231 at m/z 783 and together with daughter ions at m/z 765, 597, and 301 allowed its
232 identification as pedunculagin (*i.e.*, bis-HHDP-glucose) isomers (Calani et al., 2013;
233 Sentandreu et al., 2013). The UV spectra of Compound number 9 shows a precursor ion
234 at m/z 939 and product ions at m/z 787 and 769, attributed to the loss of a galloyl group
235 [M - 152 - H]⁻ and a water molecule [M - 152 - 18 - H]⁻, respectively. This ion fragment
236 (m/z 769) underwent then the loss of a galloyl and a water molecule, originating m/z
237 fragments of 617 and 599, respectively. Although with the absence of two MS² fragments
238 (m/z at 617 and 599) present in the UV spectra of compound number 9, compound number
239 11 was also identified as pentagalloyl-glucose (m/z 939) due to characteristic product ions
240 at m/z 787, 769, and 465, which unveil the presence of homologous series of
241 galloylglucose (Mena et al., 2012; Wyrepkowski et al., 2014). Compound number 10 and
242 12 ([M-H]⁻ at m/z 935) presented the same pseudomolecular ion and MS² product ions at
243 m/z 783, 765, 633, and 301, likely due to the loss of a water molecule, HHDP, and galloyl-
244 glucose moieties, respectively, thus being consistent with galloyl-bis-HHDP-glucose
245 isomers (Carocho et al., 2014). The fragment ions at m/z 1087, 935, and 783 present in
246 the UV spectra of compounds number 13-17, show the consecutive loss of two galloyl
247 moieties; that, together with pseudomolecular ions at 1087 and 1259 m/z allowed its
248 identification as digalloyl-bis-HHDP-glucopyranose and trigalloyl-bis-HHDP-
249 glucopyranose (Hofmann et al., 2016; Liberal et al., 2015; Salminen J-P et al., 1999).

250 Regarding flavan-3-ols, (+)-catechin (compound number 4: $[M-H]^-$ at m/z 289) was the
251 only detected compound, being identified based on the characteristic MS² fragments at
252 m/z 245 (loss of CO₂), and 203 (cleavage of the A-ring of flavan-3-ol) (Carocho et al.,
253 2014).

254 Although at different concentrations, seventeen phenolic compounds were identified in
255 all the four studied samples, being PCH the sample exhibiting higher concentrations of
256 compounds, followed by CH, being galloyl-bis-HHDP-glucose the main compound in all
257 the samples. NCH was the sample with the lowest levels of phenolic compounds (**Table**
258 **2**).

259 The most prevalent biological and pharmacological properties reported for tannins on a
260 molecular basis are superoxide anion scavenging, apoptosis, antitumor, anti-EVB, anti-
261 MRSA, and anti-plasmin inhibition, which are attributed to its strong capacity to bind to
262 proteins, large molecular compounds, and metallic ions. Galloyl moieties have been
263 identified as the most bioactive components of tannin-rich plants, playing multiple
264 functional roles such as antimicrobial, anti-inflammatory, antidiabetic, and antioxidant
265 activities (Maisetta et al., 2019). Besides, its excellent antioxidant capacity is associated
266 with chelation potency, which is mainly attributed to its catechol or galloyl moieties
267 present on the B ring of its structure (Okuda and Ito, 2011). Moreover, its tyrosinase
268 inhibition properties have been largely attributed to their competitive inhibition of
269 monophenolase and strong copper chelation activity (Niu and Aisa, 2017).

270

271 3.2. Antioxidant activity

272 Free radicals and other oxidants have played central role in the pathophysiology of
273 various diseases through several mechanisms, being lipid peroxidation one of the most
274 extensively used research model for identification of natural antioxidants (Lü et al., 2010).

275 This process is initiated when any free radical attacks and abstracts a reactive hydrogen
276 atom from a methylene group in an unsaturated fatty acid, which results in the formation
277 of a carbon-centred lipid radical. The lipid radical can then react with molecular oxygen
278 to form a lipid peroxy radical that later undergoes rearrangement to form
279 malondialdehyde (MDA) and 4-hydroxynonenal (4-HNA) (Phaniendra et al., 2015).
280 These toxic end-products cause damage to DNA, membrane proteins, enzymes, and
281 receptors, among others, which can lead to cell lysis or exacerbate the activity of various
282 cascades implicated in degenerative diseases and cancer (Phaniendra et al., 2015). Lipid
283 peroxy radicals can also further propagate the peroxidation process by abstracting
284 hydrogen atoms from the other lipid molecules. In a dose-dependent manner, both
285 methods, OxHLIA and TBARS, allowed the evaluation of the antioxidant effect of the
286 studied hydroethanolic extracts (CH, PCH, SCH, and NCH) and; although through
287 different mechanisms, both are equally a consequence of lipid peroxidation. OxHLIA
288 establishes the time and concentration at which antioxidants can retard haemolysis by
289 capturing the hydrophilic and/or lipophilic radicals, and TBARS the concentration at
290 which the extracts can prevent the formation of MDA through the donation of hydrogen
291 atoms to the lipid peroxy radical species. The obtained results for both assays are
292 displayed in **Table 3**. All the four tested extracts showed high bioactivity, on the order of
293 nanograms per millilitre, and lower IC₅₀ than the tested positive control, trolox, a water-
294 soluble analogue of vitamin E. Concerning OxHLIA assay, all the IC₅₀ values of the tested
295 extracts were approximately 30 up to 73 times lower, and for TBARS approximately 9
296 up to 16 times inferior to trolox. The lowest IC₅₀, for both assays, was obtained by the
297 petals extract (OxHLIA: 279 ng/mL ($\Delta t = 60$ min) and 384 ng/mL ($\Delta t = 120$ min);
298 TBARS: 342 ng/mL). There is certain agreement that complete based hydrogen atoms
299 transfer assays (HAT) include among others, 1,1-diphenyl-2-picrylhydrazyl radical

300 (DPPH*) and OxHLIA assays. In a 2019 study performed by Maisetta and colleagues, *C.*
301 *hypocistis* whole plant ethanolic extracts displayed strong antioxidant activity, DPPH: 6.8
302 $\pm 1.2 \mu\text{g/mL}$ (Maisetta et al., 2019). Although both studies utilised HAT *in vitro* methods,
303 the present study assay considered the level of oxidative stress in a biological sample,
304 with biological fluids and cell components present during the analysis. Despite these
305 potential external interferences, when compared, the ability of CH extracts to quench free
306 radicals by hydrogen donation was higher for the present study, 24-fold more effective.

307

308 3.3. Antibacterial activity

309 In recent years, antibiotic resistance has become an alarming issue, which increased the
310 interest on plant-derived compounds discovery as new active antibacterial agents
311 (Stojković et al., 2013). The four hydroethanolic extracts (CH, PCH, SCH and NCH) of
312 *C. hypocistis* were evaluated for their antibacterial potential against multi-resistant
313 pathogenic strains (**Table 4**), such as Gram-positive (*E. faecalis*, *L. monocytogenes*, and
314 MRSA) and Gram-negative bacteria (*E. coli*, *P. mirabilis*, *K. pneumoniae*, *P. aeruginosa*,
315 and *M. morganii*). Ampicillin is a beta-lactamic antibiotic widely used for its ability to
316 destroy Gram-positive and Gram-negative bacteria (Rozas et al., 2010). Compared to this
317 antibiotic, all the four *C. hypocistis* tested extracts were more effective against three
318 Gram-negative bacteria. Considering *K. pneumoniae*, the extracts were 2 to 8-fold more
319 effective than ampicillin. For *P. aeruginosa* and *M. morganii*, 8 to 16-fold more effective
320 than ampicillin. MBC values were not obtained for any of the tested extracts (values > 20
321 mg/mL). The MIC values shown in **Table 4** indicate that the extracts were active against
322 both Gram-negative and Gram-positive bacteria, being the first more sensitive to all the
323 plant extracts. In general, the hydroethanolic extracts from the stalks were the most (SCH
324 MIC = 0.625 - 2.5 mg/mL) and the nectar the least (NCH MIC = 2.5 - 10 mg/mL) effective

325 to inhibit both Gram-positive and Gram-negative bacteria growth. For three tested
326 microorganisms (MRSA, *K. pneumoniae*, and *P. aeruginosa*), *C. hypocistis* ethanolic
327 extracts displayed better MICs in a recent study (Maisetta et al., 2019). This could be due
328 to the use of clinical isolates in the present study, which might exhibit a higher resistance
329 profile when compared with the ATCC strains tested by Maisetta and co-workers.
330 Although both studies tested the capacity of the extracts to inhibit bacterial growth, the
331 plant material from the other study was previously resuspended in cyclohexane, the
332 collected supernatant lyophilized, and later subjected to a second extraction with ethanol.
333 The pre-extraction step reported by Maisetta et al. (2019) might also be accountable for
334 the obtained MIC values due to a higher concentration of extracted polar compounds
335 (Maisetta et al., 2019). Previous studies investigating the antimicrobial activity of tannin-
336 rich plant extracts have attributed the microbial growth inhibition to their content in
337 gallotannins and related compounds, which mainly act on the membranes of the bacteria
338 and/or their ability to complex metal ions (Maisetta et al., 2019). Several studies have
339 also shown that Gram-negative bacteria are more resistant to plant derived biomolecules
340 due to the strong repulsive negative charge of its lipopolysaccharides (Maisetta et al.,
341 2019). Contrarily, in the present work, the extracts were more effective inhibiting Gram-
342 negative bacteria, and as such, the studied extract could become a source to the discovery
343 of novel antimicrobial agents.

344

345 3.4. Antidiabetic activity

346 α -Glucosidase inhibitors fall under the third category of oral hypoglycemic agents. They
347 cleave glycosidic bonds in complex carbohydrates to release absorbable monosaccharides;
348 thus, α -glucosidase inhibitors display useful anti-hyperglycaemic effects and can be an
349 important strategy in the management of hyperglycaemia linked to type 2 diabetes

350 (Leroux-Stewart et al., 2015). Only a few α -glucosidase inhibitors are commercially
351 available, and all of them involve tedious multi-step procedures. Additionally, clinically
352 they have been associated with serious gastrointestinal side effects (Leroux-Stewart et al.,
353 2015). Therefore, the discovery of potent non-sugar based α -glucosidase inhibitors from
354 natural sources have been receiving tremendous attention, due to the highly abundant
355 compounds in nature and their promising biological activities (Yin et al., 2014). The α -
356 glucosidase inhibitor effectiveness of the different extracts (**Table 5**) was expressed on
357 the basis of resulting IC_{50} values. SCH was the best extract (0.039 mg/mL), followed by
358 CH (0.040 mg/mL), PCH (0.046 mg/mL), and NCH (0.214 mg/mL). The SCH IC_{50} was
359 approximately 21 times lower than the positive control acarbose. For PCH and CH, the
360 IC_{50} values were approximately 20 and 18 times lower, respectively. The nectar extract
361 presented a biggest IC_{50} value, approximately 2.6 times higher than acarbose. To the
362 authors' best knowledge, this is the first report evaluating the anti- α -glucosidase activity
363 of *C. hypocistis* extracts; therefore, no comparisons could be performed.

364

365 3.5. Anti-tyrosinase activity

366 Tyrosinase is widely distributed in microorganisms, animals, and plants. This binuclear
367 copper centre enzyme catalyses two distinct reactions: the hydroxylation of tyrosine by
368 monophenolase action and the oxidation of 3,4-dihydroxyphenylalanine (L-DOPA) to *o*-
369 dopaquinone through diphenolase action. Sequentially, dopaquinone can be readily
370 converted to dopachrome, an orange to red pigment (Kim and Uyama, 2005). Tyrosinase
371 catalyses the oxidation of phenolic compounds to the corresponding quinones and is
372 responsible for the enzymatic browning of fruits and vegetables, which display a
373 characteristic undesirable colour and flavour. The oxidation products of phenolic
374 compounds can then react with other food components, including amines, peptides, and

375 proteins, which further reduces food quality and digestibility (Shao et al., 2018).
376 Tyrosinase also plays a critical role in the biosynthesis of melanin and its over-activity
377 can cause skin hyperpigmentation (Niu and Aisa, 2017). Products containing ingredients
378 such as hydroquinone, kojic acid, and retinoids have been utilised in the past to suppress
379 the severity of hyperpigmentation; however, long term exposure to them have been
380 reported to present cytotoxic, irritating, and mutagenic effects on the skin (Draelos, 2007).
381 Therefore, the discovery of novel high-performance tyrosinase inhibitors is in great need
382 for the food and cosmetic field.

383 Tyrosinase inhibition was determined using purified enzyme from mushroom and
384 expressed on the basis of resulting IC₅₀ values presented on **Table 5**. To the authors' best
385 knowledge, this is the second study reporting a quantitative analysis of *C. hypocistis* anti-
386 tyrosinase activity (Maisetta et al., 2019). Although to different extents, all *C. hypocistis*
387 ethanolic extracts were able to inhibit tyrosinase activity, being the stalks the best result
388 (SCH: 0.09 mg/mL), followed by the petals (PCH: 0.19 mg/mL), whole plant (CH: 0.20
389 mg/mL), and nectar (NCH: 27.6%). For the maximum tested concentration (0.5 mg/mL),
390 NCH was only able to inhibit 27.6% of tyrosinase. SCH was the extract exhibiting the
391 closest IC₅₀ (0.09 mg/mL) value comparing to the positive control, kojic acid (0.078
392 mg/mL), one of the most intensively studied tyrosinase inhibitors (Draelos, 2007). *C.*
393 *hypocistis* whole plant displayed a better IC₅₀ (0.0098 mg/mL) in a 2019 study (Maisetta
394 et al., 2019). Similarly, to the antibacterial activity, this could be due to the pre-extraction
395 step performed by Maisetta and colleagues and therefore, the presence of a higher
396 concentration of bioactive compounds.

397

398 3.6. Anti-proliferative and hepatotoxic activity

399 Plant-derived products garner increasing attention in cancer chemotherapy, aside from
400 view as more biologically friendly, and consequently more co-evolved with their target
401 sites, there is also evidence that natural product-derived anticancer drugs have alternative
402 modes of promoting cell death (Gali-Muhtasib et al., 2015; Khalid et al., 2016). *C.*
403 *hypocistis* hydroethanolic extracts were screened for their cytotoxic activity using
404 different tumour cell lines. The sulforhodamine B colorimetric assay was applied in order
405 to determine the inhibitory growth activity of the tested extracts for four human tumour
406 cell lines: NCI-H460 (non-small cell lung cancer), HeLa (cervical carcinoma), HepG2
407 (hepatocellular carcinoma), and MCF-7 (breast carcinoma). The results (**Table 5**) are
408 expressed as GI₅₀, which represents the *C. hypocistis* extracts concentrations required to
409 inhibit 50% of cell growth. The values were in general lower (high activity), showing a
410 significant dose-dependent cytotoxic effect. In absolute terms, the cell line HepG2 was
411 the most susceptible to *C. hypocistis* extracts, followed by HeLa, NCI-H460, and MCF-
412 7. HeLa (GI₅₀ = 68 µg/mL) was the most vulnerable cell line to *C. hypocistis* extracts
413 action, namely SCH. *C. hypocistis* nectar (NCH) showed the least effective results. When
414 comparing its GI₅₀, the values were 1.44 to 2.35-fold higher than the optimal value for
415 the different tested cell lines: HeLa (NCH: 159 µg/mL versus SCH: 68 µg/mL), NCI-H46
416 (NCH: 175 µg/mL versus PCH: 93 µg/mL), MCF-7 (NCH: 206 µg/mL versus SCH: 98
417 µg/mL), and HepG2 (NCH: 110 µg/mL versus SCH: 77 µg/mL). From all the four *C.*
418 *hypocistis* extracts tested (CH, PCH, SCH and NCH), the stalks extract (SCH) exhibited
419 the best GI₅₀ values for three cell lines (HeLa, MCF-7, and HepG2). Although the petals
420 extract (PCH) presented a better GI₅₀ for one of the tested cell lines, NCI-H460, the value
421 was really similar when compared with SCH, 93 µg/mL versus 100 µg/mL.

422 To the authors' best knowledge, there are only two studies on the cytotoxic activity of *C.*
423 *hypocistis* extracts (Magiatis et al., 2001; Zucca et al., 2015). The data from the present

424 study are in accordance with that reported by Magiatis and colleagues, who found that
425 the methanolic extracts of three Greek *Cytinus* taxa exhibited cytotoxic activity against
426 several cancer cell lines (Magiatis et al., 2001). These results led the authors to the
427 fractionation of the methanolic extracts by medium pressure liquid chromatography
428 (MPLC), obtaining an inactive fraction ($GI_{50} > 400$), containing mainly sugars, and a
429 fraction with increased cytotoxicity when compared to the total methanolic extracts. For
430 the two species of *C. hypocistis* studied by Magiatis and co-workers, methanolic extracts
431 exhibited GI_{50} of 100 and 98 $\mu\text{g/mL}$ for human mammary adenocarcinoma (MDA-MB-
432 231), in contrast with GI_{50} of 75 and 77 $\mu\text{g/mL}$ for the cytotoxic active fraction. Similar
433 results were obtained for human bladder transitional cell carcinoma (BC3c), 110 and 105
434 $\mu\text{g/mL}$, in contrast with 71 and 67 $\mu\text{g/mL}$ for the active fraction (Magiatis et al., 2001).
435 The authors attributed this cytotoxic activity to hydrolysable tannins, without any obvious
436 dependence on their molecular weights. Although in the present work different cell lines
437 were used, both studies exhibited a similar range of GI_{50} regarding total extracts analysis.
438 Because porcine hepatocytes are close to human hepatocytes in terms of metabolism and
439 ammonia elimination, the four *C. hypocistis* extracts were tested for their hepatotoxic
440 activity on non-tumour porcine liver cells (PLP2) (**Table 5**), and up to the maximal tested
441 concentration (400 $\mu\text{g/mL}$) no toxicity was observed (Shi et al., 2016).

442

443 3.7. Anti-inflammatory activity

444 Macrophages play an essential role in the anti-inflammatory process and can be activated
445 by interferon gamma ($\text{IFN-}\gamma$), interleukins (IL-4, IL-10, IL-13), transforming growth
446 factor beta ($\text{TGF-}\beta$), and some structures from pathogenic microorganisms such as
447 lipopolysaccharides (LPS) (Pohanka et al., 2011). During pathogen invasion,
448 immunocytes secrete inflammatory mediators, such as nitric oxide (NO) and

449 prostaglandin E2 (PGE2), via the inducible nitric oxide synthase (iNOS) and
450 cyclooxygenase-2 (COX-2). iNOS and COX-2 are involved in tumour progression
451 through various mechanisms, including inhibition of apoptosis, stimulation of
452 angiogenesis and promotion of tumour cell proliferation (Guo et al., 2014). All the four
453 *C. hypocistis* extracts successfully reduced the expression of the anti-inflammatory
454 enzyme iNOS, in LPS-activated murine macrophages. NO reduction was measured
455 employing a Griess reagent system kit and expressed as lower IC₅₀ values (**Table 5**).
456 Among all extracts, the petals extract (PCH) showed the highest inhibitory effects in NO
457 production by LPS-stimulated RAW264.7 cells (IC₅₀ = 127 µg/mL), followed by SCH
458 (IC₅₀ = 127 µg/mL), CH (IC₅₀ = 136 µg/mL), and NCH (IC₅₀ = 277 µg/mL). To the
459 authors' best knowledge, this is novel study regarding the anti-inflammatory activity of
460 *C. hypocistis* and thus no comparisons could be performed.

461

462 **4. Conclusion**

463 In this study, the chemical fingerprint of *Cytinus hypocistis* (L.) L. hydroethanolic
464 extracts was determined and its antioxidant, antibacterial, antidiabetic, anti-tyrosinase,
465 anti-proliferative, hepatotoxic, and anti-inflammatory properties evaluated. A total of 17
466 phenolic compounds were identified, being galloyl-bis-HHDP-glucose, digalloyl-bis-
467 HHDP-glucofuranose, and Trigalloyl-bis-HHDP-glucose the most abundant. In absolute
468 terms, SCH was the extract exhibiting higher antibacterial, antidiabetic, anti-tyrosinase,
469 and anti-proliferative activity, followed by the PCH extract. Regarding the anti-
470 inflammatory and antioxidant properties, PCH exhibited the best results. Although for the
471 four studied samples the 17 identified phenolic compounds were the same, its
472 concentration was higher in the petals extract, followed by the stalks, being these the two
473 parts of *C. hypocistis* unveiling the strongest colours. These results point a potential

474 correlation between the phenolic profile of *C. hypocistis* and its properties. All these
475 bioactive effects, with no evidence of cytotoxicity in a non-tumour cell line, could make
476 this plant ideal to be explored for the development of herbal formulations and bio-based
477 ingredients. For its bioactivity validation and mechanism investigation, further studies on
478 fractionation, isolation and characterization of compounds of the extracts of *C. hypocistis*
479 are currently under way.

480

481 **Acknowledgements**

482 The authors are grateful to the Foundation for Science and Technology (FCT, Portugal)
483 and FEDER under Programme PT2020 for financial support to CIMO
484 (UID/AGR/00690/2019). L. Barros, J. Pinela, M.I. Dias and R.C. Calhelha thank the
485 national funding by FCT, P.I., through the institutional scientific employment program-
486 contract for their contracts. The authors are also grateful to FEDER-Interreg España-
487 Portugal programme for financial support through the project 0377_Iberphenol_6_E and
488 TRANSCoLAB 0612_TRANS_CO_LAB_2_P.

489

490 **Conflicts of Interest**

491 The authors state no conflict of interest.

492

493 **References**

- 494 Balunas, M.J., Kinghorn, A.D., 2005. Drug discovery from medicinal plants. *Life Sci.* 78,
495 431–441.
- 496 Bessada, S.M.F., Barreira, J.C.M., Barros, L., Ferreira, I.C.F.R., Oliveira, M.B.P.P.,
497 2016. Phenolic profile and antioxidant activity of *Coleostephus myconis* (L.)
498 Rchb.f.: An underexploited and highly disseminated species. *Ind. Crops Prod.* 89,

499 45–51.

500 Calani, L., Beghè, D., Mena, P., Del Rio, D., Bruni, R., Fabbri, A., Dall'Asta, C.,
501 Galaverna, G., 2013. Ultra-HPLC–MSⁿ (Poly)phenolic profiling and chemometric
502 analysis of juices from ancient *Punica granatum* L. cultivars: A nontargeted
503 approach. *J. Agric. Food Chem.* 61, 5600–5609.

504 Carocho, M., Barros, L., Bento, A., Santos-Buelga, C., Morales, P., Ferreira, I.C.F.R.,
505 2014. *Castanea sativa* Mill. Flowers amongst the most powerful antioxidant
506 matrices: a phytochemical approach in decoctions and infusions. *Biomed Res. Int.*
507 2014, 232956.

508 Chen, C.-H., Chan, H.-C., Chu, Y.-T., Ho, H.-Y., Chen, P.-Y., Lee, T.-H., Lee, C.-K.,
509 2009. Antioxidant activity of some plant extracts towards xanthine oxidase,
510 lipoxygenase and tyrosinase. *Molecules* 14, 2947–58.

511 Draelos, Z.D., 2007. Skin lightening preparations and the hydroquinone controversy.
512 *Dermatol. Ther.* 20, 308–313.

513 Gali-Muhtasib, H., Hmadi, R., Kareh, M., Tohme, R., Darwiche, N., 2015. Cell death
514 mechanisms of plant-derived anticancer drugs: beyond apoptosis. *Apoptosis* 20,
515 1531–1562.

516 Graça, V.C., Barros, L., Calhella, R.C., Dias, M.I., Carvalho, A.M., Santos-Buelga, C.,
517 Ferreira, I.C.F.R., Santos, P.F., 2016. Chemical characterization and bioactive
518 properties of *Geranium molle* L.: from the plant to the most active extract and its
519 phytochemicals. *Food Funct.* 7, 2204–12.

520 Guimarães, R., Barros, L., Dueñas, M., Calhella, R.C., Carvalho, A.M., Santos-Buelga,
521 C., Queiroz, M.J.R.P., Ferreira, I.C.F.R., 2013. Nutrients, phytochemicals and
522 bioactivity of wild *Roman chamomile*: A comparison between the herb and its
523 preparations. *Food Chem.* 136, 718–725.

524 Guo, Y., Sakulnarmrat, K., Konczak, I., 2014. Anti-inflammatory potential of native
525 Australian herbs polyphenols. *Toxicol. Reports* 1, 385–390.

526 Hofmann, T., Nebehaj, E., Albert, L., 2016. Antioxidant properties and detailed
527 polyphenol profiling of European hornbeam (*Carpinus betulus* L.) leaves by
528 multiple antioxidant capacity assays and high-performance liquid
529 chromatography/multistage electrospray mass spectrometry. *Ind. Crops Prod.* 87,
530 340–349.

531 Khalid, E.B., Ayman, E.-M.E.-K., Rahman, H., Abdelkarim, G., Najda, A., 2016. Natural
532 products against cancer angiogenesis. *Tumor Biol.* 37, 14513–14536.

533 Kim, Y.-J., Uyama, H., 2005. Tyrosinase inhibitors from natural and synthetic sources:
534 structure, inhibition mechanism and perspective for the future. *Cell. Mol. Life Sci.*
535 62, 1707–1723.

536 Leroux-Stewart, J., Rabasa-Lhoret, R., Chiasson, J.-L., 2015. α -Glucosidase inhibitors,
537 In: *International Textbook of Diabetes Mellitus*. John Wiley & Sons, Ltd,
538 Chichester, UK, pp. 673–685.

539 Les, F., Venditti, A., Cásedas, G., Frezza, C., Guiso, M., Sciubba, F., Serafini, M., Bianco,
540 A., Valero, M.S., López, V., 2017. Everlasting flower (*Helichrysum stoechas*
541 Moench) as a potential source of bioactive molecules with antiproliferative,
542 antioxidant, antidiabetic and neuroprotective properties. *Ind. Crops Prod.* 108, 295–
543 302.

544 Liberal, J., Costa, G., Carmo, A., Vitorino, R., Marques, C., Domingues, M.R.,
545 Domingues, P., Gonçalves, A.C., Alves, R., Sarmiento-Ribeiro, A.B., Girão, H.,
546 Cruz, M.T., Batista, M.T., 2015. Chemical characterization and cytotoxic potential
547 of an ellagitannin-enriched fraction from *Fragaria vesca* leaves. *Arab. J. Chem.*
548 Article in press. <https://doi.org/10.1016/j.arabjc.2015.11.014>

549 Lockowandt, L., Pinela, J., Roriz, C.L., Pereira, C., Abreu, R.M.V., Calhelha, R.C.,
550 Alves, M.J., Barros, L., Bredol, M., Ferreira, I.C.F.R., 2019. Chemical features and
551 bioactivities of cornflower (*Centaurea cyanus* L.) capitula: The blue flowers and the
552 unexplored non-edible part. *Ind. Crops Prod.* 128, 496–503.

553 Lü, J.-M., Lin, P.H., Yao, Q., Chen, C., 2010. Chemical and molecular mechanisms of
554 antioxidants: experimental approaches and model systems. *J. Cell. Mol. Med.* 14,
555 840–860.

556 Magiatis, P., Pratsinis, H., Kalpoutzakis, E., Konstantinidou, A., Davaris, P., Skaltsounis,
557 A.-L., 2001. Hydrolyzable tannins, the active constituents of three Greek *Cytinus*
558 *Taxa* against several tumor cell lines. *Biol. Pharm. Bull.* 24, 707–709.

559 Maisetta, G., Batoni, G., Caboni, P., Esin, S., Rinaldi, A.C., Zucca, P., 2019. Tannin
560 profile, antioxidant properties, and antimicrobial activity of extracts from two
561 Mediterranean species of parasitic plant *Cytinus*. *BMC Complement. Altern. Med.*
562 19, 82.

563 Mena, P., Calani, L., Dall'Asta, C., Galaverna, G., García-Viguera, C., Bruni, R., Crozier,
564 A., Del Rio, D., 2012. Rapid and comprehensive evaluation of (poly)phenolic
565 compounds in pomegranate (*Punica granatum* L.) juice by UHPLC-MSⁿ. *Molecules*
566 17, 14821–14840.

567 Niu, C., Aisa, H.A., 2017. Upregulation of melanogenesis and tyrosinase activity:
568 potential agents for vitiligo. *Mol. A J. Synth. Chem. Nat. Prod. Chem.* 22, 1303.

569 Okuda, T., Ito, H., 2011. Tannins of constant structure in medicinal and food plants-
570 hydrolyzable tannins and polyphenols related to tannins. *Molecules* 16, 2191–2217.

571 Owen, R.W., Haubner, R., Hull, W.E., Erben, G., Spiegelhalder, B., Bartsch, H., Haber,
572 B., 2003. Isolation and structure elucidation of the major individual polyphenols in
573 carob fibre. *Food Chem. Toxicol.* 41, 1727–1738.

574 Petersen, M., Hans, J., Ulrich, M., 2010. *Biochemistry of Plant Secondary Metabolism*.
575 Wiley-Blackwell, Oxford, UK.

576 Phaniendra, A., Jestadi, D.B., Periyasamy, L., 2015. Free radicals: properties, sources,
577 targets, and their implication in various diseases. *Indian J. Clin. Biochem.* 30, 11–
578 26.

579 Phillipson, J.D., 2007. Phytochemistry and pharmacognosy. *Phytochemistry* 68, 2960–
580 2972.

581 Pires, T.C.S.P., Dias, M.I., Barros, L., Alves, M.J., Oliveira, M.B.P.P., Santos-Buelga,
582 C., Ferreira, I.C.F.R., 2018. Antioxidant and antimicrobial properties of dried
583 Portuguese apple variety (*Malus domestica* Borkh. cv Bravo de Esmolfe). *Food*
584 *Chem.* 240, 701–706.

585 Pohanka, M., Snopkova, S., Havlickova, K., Bostik, P., Sinkorova, Z., Fusek, J., Kuca,
586 K., Pikula, J., 2011. Macrophage-assisted inflammation and pharmacological
587 regulation of the cholinergic anti-inflammatory pathway. *Curr. Med. Chem.* 18,
588 539–51.

589 Rozas, O., Contreras, D., Mondaca, M.A., Pérez-Moya, M., Mansilla, H.D., 2010.
590 Experimental design of Fenton and photo-Fenton reactions for the treatment of
591 ampicillin solutions. *J. Hazard. Mater.* 177, 1025–1030.

592 Salminen J-P, Ossipov, V., Loponen, J., Haukioja, E., Pihlaja, K., 1999. Characterisation
593 of hydrolysable tannins from leaves of *Betula pubescens* by high-performance liquid
594 chromatography-mass spectrometry. *J. Chromatogr. A* 864, 283–91.

595 Sentandreu, E., Cerdán-Calero, M., Sendra, J.M., 2013. Phenolic profile characterization
596 of pomegranate (*Punica granatum*) juice by high-performance liquid
597 chromatography with diode array detection coupled to an electrospray ion trap mass
598 analyzer. *J. Food Compos. Anal.* 30, 32–40.

599 Shao, L.-L., Wang, X.-L., Chen, K., Dong, X.-W., Kong, L.-M., Zhao, D.-Y., Hider, R.C.,
600 Zhou, T., 2018. Novel hydroxypyridinone derivatives containing an oxime ether
601 moiety: Synthesis, inhibition on mushroom tyrosinase and application in anti-
602 browning of fresh-cut apples. *Food Chem.* 242, 174–181.

603 Shi, X.-L., Gao, Y., Yan, Y., Ma, H., Sun, L., Huang, P., Ni, X., Zhang, L., Zhao, X.,
604 Ren, H., Hu, D., Zhou, Y., Tian, F., Ji, Y., Cheng, X., Pan, G., Ding, Y.-T., Hui, L.,
605 2016. Improved survival of porcine acute liver failure by a bioartificial liver device
606 implanted with induced human functional hepatocytes. *Cell Res.* 26, 206–216.

607 Silva, A.R., Fernandes, Â., García, P.A., Barros, L., Ferreira, I.C.F.R., Silva, A.R.,
608 Fernandes, Â., García, P.A., Barros, L., Ferreira, I.C.F.R., 2019. *Cytinus hypocistis*
609 (L.) L. subsp. *macranthus* Wettst.: Nutritional characterization. *Molecules* 24, 1111.

610 Souilem, F., Fernandes, Â., Calhella, R.C., Barreira, J.C.M., Barros, L., Skhiri, F.,
611 Martins, A., Ferreira, I.C.F.R., 2017. Wild mushrooms and their mycelia as sources
612 of bioactive compounds: Antioxidant, anti-inflammatory and cytotoxic properties.
613 *Food Chem.* 230, 40–48.

614 Spínola, V., Castilho, P.C., 2017. Evaluation of Asteraceae herbal extracts in the
615 management of diabetes and obesity. Contribution of caffeoylquinic acids on the
616 inhibition of digestive enzymes activity and formation of advanced glycation end-
617 products (*in vitro*). *Phytochemistry* 143, 29–35.

618 Stojković, D., Petrović, J., Soković, M., Glamočlija, J., Kukić-Marković, J., Petrović, S.,
619 2013. *In situ* antioxidant and antimicrobial activities of naturally occurring caffeic
620 acid, *p*-coumaric acid and rutin, using food systems. *J. Sci. Food Agric.* 93, 3205–
621 3208.

622 Tan, H.P., Ling, S.K., Chuah, C.H., 2011. Characterisation of galloylated cyanogenic
623 glucosides and hydrolysable tannins from leaves of *Phyllagathis rotundifolia* by LC-

624 ESI-MS/MS. *Phytochem. Analysis* 22, 516-525.

625 Wyrepkowski, C., Gomes da Costa, D., Sinhorin, A., Vilegas, W., De Grandis, R.,
626 Resende, F., Varanda, E., dos Santos, L., 2014. Characterization and quantification
627 of the compounds of the ethanolic extract from *Caesalpinia ferrea* stem bark and
628 evaluation of their mutagenic activity. *Molecules* 19, 16039–16057.

629 Yin, Z., Zhang, W., Feng, F., Zhang, Y., Kang, W., 2014. α -Glucosidase inhibitors
630 isolated from medicinal plants. *Food Sci. Hum. Wellness* 3, 136–174.

631 Zucca, P., Pintus, M., Manzo, G., Nieddu, M., Steri, D., Rinaldi, A.C., 2015.
632 Antimicrobial, antioxidant and anti-tyrosinase properties of extracts of the
633 Mediterranean parasitic plant *Cytinus hypocistis*. *BMC Res. Notes* 8, 562.

Figure captions

Figure 1. A: Graphical representation of the four different studied parts of *C. hypocistis*; and B: Phenolic profile of *C. hypocistis* petals extract (PCH) recorded at 280 nm.

Tables

Table 1. Phenolic compounds identified in *C. hypocistis* extracts. Retention time (Rt), wavelength of maximum absorption in the UV-vis region (λ_{\max}), pseudomolecular and MS² fragment ions and relative abundance in brackets.

Peak	Rt (min)	λ_{\max} (nm)	[M-H] ⁻ (m/z)	MS ² (m/z)	Tentative identification	References
1	4.42	275	331	169(100), 125(9)	Galloyl-glucose	Tan, Ling, & Chuah, 2011
2	4.83	275	483	331(100), 169(50), 125(9)	Digalloyl-glucose	Tan, Ling, & Chuah, 2011
3	6.28	275	635	483(22), 465(100), 421(6), 313(5), 169(38), 125(5)	Trigalloyl-glucose	Mena et al., 2012; Tan et al., 2011
4	7.03	280	289	245(100), 203 (10), 137(5)	(+)-Catechin	Carocho et al., 2014; Rockenbach et al., 2012
5	9.25	275	635	483(17), 465(100), 421(5), 313(5), 169(25), 125(5)	Trigalloyl-glucose	Mena et al., 2012; Tan et al., 2011
6	14.83	275	937	787(36), 767(100), 637(22), 467(41), 301(38)	Trigalloyl-HHDP-glucose	Carocho et al., 2014
7	15.46	275	787	635(26), 617(100), 465(5)	Tetragalloyl-glucoside	Owen et al., 2003
8	16.7	278	783	765(65), 597(100), 301(15)	Pedunculagin (bis-HHDP-glucose)	Calani et al., 2013; Sentandreu et al., 2013
9	19.14	275	939	787(100), 769(70), 617(5), 601(5), 599(46), 465(5), 301(4)	Pentagalloyl-glucose	Mena et al., 2012; Wyrepkowski et al., 2014
10	19.43	278	935	783(100), 765(13), 633(5), 301(5)	Galloyl-bis-HHDP-glucose	Carocho et al., 2014
11	20.79	275	939	787(100), 769(5), 465(8), 301(3)	Pentagalloyl-glucose	Mena et al., 2012; Wyrepkowski et al., 2014
12	21.8	278	935	783(100), 765(15), 633(8), 301(7)	Galloyl-bis-HHDP-glucose	Carocho et al., 2014
13	22.63	278	1087	935(100), 783(20), 633(3), 301(11)	Digalloyl-bis-HHDP-glucos	Hofmann et al., 2016; Liberal et al., 2015
14	24.11	277	1087	935(100), 783(18), 633(5), 301(14)	Digalloyl-bis-HHDP-glucose	Hofmann et al., 2016; Liberal et al., 2015
15	25.2	277	1087	935(100), 783(18), 633(5), 301(14)	Digalloyl-bis-HHDP-glucose	Hofmann et al., 2016; Liberal et al., 2015;
16	26.56	276	1259	1087(100), 935(66), 783(15), 633(5), 301(12)	Trigalloyl-bis-HHDP-glucose	Hofmann et al., 2016; Liberal et al., 2015
17	27.75	276	1259	1087(100), 935(55), 783(13), 633(5), 301(10)	Trigalloyl-bis-HHDP-glucose	Hofmann et al., 2016; Liberal et al., 2015

Table 2. Phenolic compounds quantification in *C. hypocistis* extracts.

Peak	Tentative identification	Content (mg/g extract)			
		CH	PCH	SCH	NCH
1	Galloyl-glucose ¹	0.81 ± 0.01 ^c	1.9 ± 0.05 ^a	1.19 ± 0.08 ^b	0.77 ± 0.05 ^c
2	Digalloyl-glucose ¹	0.99 ± 0.01 ^b	1.68 ± 0.03 ^a	0.335 ± 0.004 ^d	0.65 ± 0.02 ^c
3	Trigalloyl-glucose ¹	1.47 ± 0.04 ^a	0.46 ± 0.04 ^b	1.49 ± 0.07 ^a	0.146 ± 0.003 ^c
4	(+)-Catechin ²	1.83 ± 0.04 ^c	2.9 ± 0.1 ^a	2.17 ± 0.06 ^b	1.69 ± 0.03 ^d
5	Trigalloyl-glucose ¹	1.09 ± 0.03 ^b	1.41 ± 0.06 ^a	0.64 ± 0.03 ^c	tr
6	Trigalloyl-HHDP-glucose ¹	1.26 ± 0.04 ^c	1.88 ± 0.03 ^b	2.52 ± 0.08 ^a	0.29 ± 0.01 ^d
7	Tetragalloyl-glucoside ¹	1.907 ± 0.004 ^b	1.13 ± 0.02 ^c	2.7 ± 0.1 ^a	0.114 ± 0.005 ^d
8	Pedunculagin (bis-HHDP-glucose) ³	2.23 ± 0.03 ^b	3.34 ± 0.05 ^a	1.63 ± 0.04 ^c	tr
9	Pentagalloyl-glucose ¹	5.10 ± 0.04 ^a	5.3 ± 0.2 ^a	3.7 ± 0.2 ^b	1.43 ± 0.06 ^c
10	Galloyl-bis-HHDP-glucose ³	42 ± 1 ^a	41 ± 1 ^a	34 ± 1 ^b	5.43 ± 0.05 ^c
11	Pentagalloyl-glucose ¹	0.85 ± 0.03 ^b	2.80 ± 0.01 ^a	0.14 ± 0.01 ^c	0.114 ± 0.004 ^c
12	Galloyl-bis-HHDP-glucose ³	9.60 ± 0.05 ^b	11.1 ± 0.3 ^a	6.8 ± 0.3 ^c	2.1 ± 0.1 ^d
13	Digalloyl-bis-HHDP-glucos ³	6.45 ± 0.01 ^a	6.5 ± 0.2 ^a	5.1 ± 0.1 ^b	1.74 ± 0.02 ^c
14	Digalloyl-bis-HHDP-glucose ³	18.3 ± 0.4 ^b	27.2 ± 0.1 ^a	11.4 ± 0.2 ^c	3.64 ± 0.02 ^d
15	Digalloyl-bis-HHDP-glucose ³	5.4 ± 0.1 ^b	7.7 ± 0.1 ^a	1.65 ± 0.02 ^c	1.78 ± 0.02 ^c
16	Trigalloyl-bis-HHDP-glucose ³	2.58 ± 0.02 ^c	13.1 ± 0.7 ^a	4.2 ± 0.1 ^b	1.30 ± 0.01 ^d
17	Trigalloyl-bis-HHDP-glucose ³	nd	7.4 ± 0.3 [*]	2.35 ± 0.01 [*]	nd
Σ Phenolic compounds		102.0 ± 0.6 ^b	137 ± 2 ^a	82 ± 2 ^c	21.2 ± 0.2 ^d

CH: whole plant extract; PCH: petals extract; SCH: stalks extract; NCH: nectar extract. Standard calibration curves recorded at 280 nm: (1)- Gallic acid ($y = 131538x + 292163$; $R^2 = 0.9998$; LOD = 0.68 µg/mL; LOQ = 1.61 µg/mL); (2)- catechin ($y = 84950x + 23200$; $R^2 = 0.9999$; LOD = 0.17 µg/mL; LOQ = 0.68 µg/mL); (3)- Ellagic acid ($y = 26719x - 317255$; $R^2 = 0.9996$; LOD = 0.10 µg/mL; LOQ = 0.48 µg/mL). In each row, different letters correspond to significant differences ($p < 0.05$) between samples. *Means statistical differences obtained by a *t*-student test.

Table 3. Antioxidant activity of *C. hypocistis* extracts and positive control measured by the cell-based assays of OxHLIA and TBARS.

	OxHLIA (IC ₅₀ , ng/mL)		TBARS (IC ₅₀ , ng/mL)
	$\Delta t = 60$ min	$\Delta t = 120$ min	
CH	285 ± 4 ^{b,c}	406 ± 5 ^c	413 ± 9 ^c
PCH	279 ± 5 ^{c,d}	384 ± 9 ^c	342 ± 2 ^d
SCH	306 ± 2 ^b	458 ± 4 ^b	634 ± 12 ^a
NCH	672 ± 15 ^a	1032 ± 28 ^a	551 ± 13 ^b
Trolox*	20384 ± 363	44212 ± 1500	5389 ± 320

CH: whole plant extract; PCH: petals extract; SCH: stalks extract; NCH: nectar extract. The results are presented as mean ± standard deviation and expressed as IC₅₀ values, which correspond to the extract concentration in ng/mL required to protect 50% of the erythrocyte population from haemolysis for Δt of 60 min and 120 min or to provide 50% of antioxidant activity in the OxHLIA and TBARS assays, respectively. In each column, different letters correspond to significant differences ($p < 0.05$) between samples. *Trolox differs significantly from the plant extracts ($p < 0.05$).

Table 4. Antibacterial activity of *C. hypocistis* extracts and positive controls.

	CH		PCH		SCH		NCH		Ampicillin		Imipenem		Vancomycin	
	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC
Gram-negative bacteria														
<i>Escherichia coli</i>	1.25	>20	1.25	>20	0.625	>20	2.5	>20	<0.15	<0.15	<0.0078	<0.0078	n.t.	n.t.
<i>Klebsiella pneumoniae</i>	1.25	>20	1.25	>20	1.25	>20	5	>20	10	20	<0.0078	<0.0078	n.t.	n.t.
<i>Morganella morganii</i>	1.25	>20	2.5	>20	1.25	>20	2.5	20	20	>20	<0.0078	<0.0078	n.t.	n.t.
<i>Proteus mirabilis</i>	1.25	20	1.25	20	1.25	20	5	>20	<0.15	<0.15	<0.0078	<0.0078	n.t.	n.t.
<i>Pseudomonas aeruginosa</i>	2.5	>20	2.5	>20	1.25	>20	2.5	>20	>20	>20	0.5	1	n.t.	n.t.
Gram-positive bacteria														
<i>Enterococcus faecalis</i>	2.5	20	2.5	>20	2.5	>20	5	>20	<0.15	<0.15	n.t.	n.t.	<0.0078	<0.0078
<i>Listeria monocytogenes</i>	2.5	>20	2.5	>20	2.5	>20	10	>20	<0.15	<0.15	<0.0078	<0.0078	n.t.	n.t.
MRSA	1.25	>20	1.25	>20	0.625	>20	2.5	>20	<0.15	<0.15	n.t.	n.t.	0.25	0.5

CH: whole plant extract; PCH: petals extract; SCH: stalks extract; NCH: nectar extract; n.t.: not tested; MRSA: Methicillin Resistant *Staphylococcus aureus*; MIC: Minimum inhibitory concentration in mg/mL; MBC: Minimum bactericidal concentration in mg/mL.

Table 5. Enzyme inhibitory, anti-proliferative, hepatotoxic, and anti-inflammatory properties of *C. hypocistis* extracts and positive controls.

	CH	PCH	SCH	NCH	Positive control
	Antidiabetic activity (IC₅₀, mg/mL)				Acarbose
α-Glucosidase	0.040 ± 0.001 ^c	0.046 ± 0.004 ^c	0.039 ± 0.001 ^c	0.214 ± 0.005 ^b	0.83 ± 0.02 ^a
	Tyrosinase inhibition activity (IC₅₀, mg/mL)				Kojic acid
Tyrosinase	0.20 ± 0.01 ^a	0.19 ± 0.01 ^b	0.09 ± 0.02 ^c	27.6 ± 0.7%*	0.078 ± 0.001 ^d
	Cytotoxic activity (GI₅₀, µg/mL)				Ellipticine**
HeLa	80 ± 7 ^b	71 ± 2 ^b	68 ± 4 ^b	159 ± 5 ^a	1.91 ± 0.06
NCI-H460	102 ± 4 ^b	93 ± 8 ^b	100 ± 6 ^b	175 ± 13 ^a	1.03 ± 0.09
MCF-7	117 ± 6 ^b	103 ± 7 ^b	98 ± 4 ^b	206 ± 11 ^a	1.1 ± 0.2
HepG2	80 ± 2 ^{b,c}	90 ± 6 ^b	77 ± 2 ^c	110 ± 3 ^a	1.1 ± 0.2
PLP2	>400	>400	>400	>400	3.2 ± 0.7
	Anti-inflammatory activity (IC₅₀, µg/mL)				Dexamethasone**
RAW 264.7	136 ± 11 ^b	127 ± 8 ^c	127 ± 12 ^c	277 ± 14 ^a	16 ± 1

CH: whole plant extract; PCH: petals extract; SCH: stalks extract; NCH: nectar extract. The results are presented as mean ± standard deviation and expressed as IC₅₀ (extract concentration in mg/mL responsible for 50% enzyme inhibition), GI₅₀ (extract concentration in µg/mL responsible for 50% of growth inhibition in human tumour cell lines and a liver primary cell culture) or IC₅₀ (extract concentration in µg/mL responsible for 50% inhibition in NO production) values. *Result given as percentage inhibition at 0.5 mg/mL. In each row, different letters correspond to significant differences ($p < 0.05$) between samples.

**The positive control differs significantly from the plant extracts ($p < 0.05$).